Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Volitionrx (VNRX) EBITDA (2019 - 2025)

Historic EBITDA for Volitionrx (VNRX) over the last 9 years, with Q3 2025 value amounting to -$5.4 million.

  • Volitionrx's EBITDA rose 1036.7% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.6 million, marking a year-over-year increase of 2204.66%. This contributed to the annual value of -$27.1 million for FY2024, which is 2395.93% up from last year.
  • Volitionrx's EBITDA amounted to -$5.4 million in Q3 2025, which was up 1036.7% from -$6.9 million recorded in Q2 2025.
  • Over the past 5 years, Volitionrx's EBITDA peaked at -$5.4 million during Q3 2025, and registered a low of -$9.5 million during Q2 2023.
  • Its 5-year average for EBITDA is -$7.3 million, with a median of -$7.5 million in 2022.
  • Per our database at Business Quant, Volitionrx's EBITDA plummeted by 6788.6% in 2021 and then surged by 3619.53% in 2024.
  • Over the past 5 years, Volitionrx's EBITDA (Quarter) stood at -$8.8 million in 2021, then rose by 15.49% to -$7.4 million in 2022, then dropped by 18.46% to -$8.8 million in 2023, then skyrocketed by 36.2% to -$5.6 million in 2024, then grew by 4.0% to -$5.4 million in 2025.
  • Its EBITDA stands at -$5.4 million for Q3 2025, versus -$6.9 million for Q2 2025 and -$5.7 million for Q1 2025.